ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
67,497.14
-2.74%
S&P 500
5,283.92
-0.39%
Dow Jones
38,734.58
-0.86%
US Dollar vs Yen
157.13
0.18%
Brent Oil
84.14
1.56%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Calliditas Therapeutics AB (CALT)

  7. Calliditas Therapeutics AB (CALT) ニュース

CALT

Calliditas Therapeutics AB (CALT)

Calliditas Therapeutics AB
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:CALT
日付受信時刻ニュースソース見出しコード企業名
2024/05/2821 : 46PR Newswire (US)Calliditas Therapeutics Presents Data at the 61st European Renal Association CongressNASDAQ:CALTCalliditas Therapeutics AB
2024/05/2821 : 36PR Newswire (US)Calliditas Therapeutics Presents Data at the 61st European Renal Association CongressNASDAQ:CALTCalliditas Therapeutics AB
2024/05/2821 : 28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
2024/05/2821 : 09Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CALTCalliditas Therapeutics AB
2024/05/2816 : 17PR Newswire (US)Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationNASDAQ:CALTCalliditas Therapeutics AB
2024/05/2816 : 14PR Newswire (US)Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationNASDAQ:CALTCalliditas Therapeutics AB
2024/05/2405 : 19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
2024/05/2314 : 55PR Newswire (US)Calliditas Q1 report, January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
2024/05/2314 : 52PR Newswire (US)Calliditas Q1 report, January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
2024/05/1705 : 05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
2024/05/1615 : 45PR Newswire (US)Invitation to the presentation of Calliditas´s interim report January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
2024/05/1615 : 43PR Newswire (US)Invitation to the presentation of Calliditas´s interim report January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
2024/05/1521 : 30PR Newswire (US)Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmNASDAQ:CALTCalliditas Therapeutics AB
2024/05/1521 : 24PR Newswire (US)Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmNASDAQ:CALTCalliditas Therapeutics AB
2024/05/1520 : 36PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
2024/05/1520 : 30PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
2024/05/1420 : 52PR Newswire (US)Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaNASDAQ:CALTCalliditas Therapeutics AB
2024/05/1420 : 35PR Newswire (US)Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaNASDAQ:CALTCalliditas Therapeutics AB
2024/05/0615 : 16PR Newswire (US)Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibNASDAQ:CALTCalliditas Therapeutics AB
2024/05/0615 : 11PR Newswire (US)Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibNASDAQ:CALTCalliditas Therapeutics AB
2024/04/2502 : 35PR Newswire (US)Calliditas Therapeutics' 2023 Annual Report PublishedNASDAQ:CALTCalliditas Therapeutics AB
2024/04/2502 : 26PR Newswire (US)Calliditas Therapeutics' 2023 Annual Report PublishedNASDAQ:CALTCalliditas Therapeutics AB
2024/04/2416 : 30PR Newswire (US)Calliditas Announces Positive NefIgArd Open Label Extension ResultsNASDAQ:CALTCalliditas Therapeutics AB
2024/04/2416 : 26PR Newswire (US)Calliditas Announces Positive NefIgArd Open Label Extension ResultsNASDAQ:CALTCalliditas Therapeutics AB
2024/04/1820 : 13PR Newswire (US)Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024NASDAQ:CALTCalliditas Therapeutics AB
2024/04/1820 : 10PR Newswire (US)Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024NASDAQ:CALTCalliditas Therapeutics AB
2024/04/0920 : 24PR Newswire (US)Calliditas Therapeutics to Attend Conferences in AprilNASDAQ:CALTCalliditas Therapeutics AB
2024/04/0920 : 22PR Newswire (US)Calliditas Therapeutics to Attend Conferences in AprilNASDAQ:CALTCalliditas Therapeutics AB
2024/04/0821 : 38PR Newswire (US)Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresNASDAQ:CALTCalliditas Therapeutics AB
2024/04/0821 : 32PR Newswire (US)Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresNASDAQ:CALTCalliditas Therapeutics AB
 Showing the most relevant articles for your search:NASDAQ:CALT

最近閲覧した銘柄

COIN
VIUUST
LSE
BV53
Barclays 29
COIN
HODLGBP
KUCN
PZPUSDT
PLAYZAP
NASDAQ
HLXB
Helix Acquisition Corpor...
OKEX
INTETH
Internet Node Token
BIT
P1QKN9
BNP Paribas Issuance
LSE
OCL
Oakley
ASX
TAR
Taruga Minerals
LSE
PUT
Premier Utilities Trust
EU
S863S
S863S
COIN
CWARUST
Cryowar Token
COIN
CABOXEUR
LQID
XCFBTC
ASX
CSLKOY
NASDAQ
FTUSAX
Cboe Vest Large Cap Deep...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有